1. Home
  2. CHPT vs RANI Comparison

CHPT vs RANI Comparison

Compare CHPT & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ChargePoint Holdings Inc.

CHPT

ChargePoint Holdings Inc.

HOLD

Current Price

$6.14

Market Cap

125.1M

ML Signal

HOLD

Logo Rani Therapeutics Holdings Inc.

RANI

Rani Therapeutics Holdings Inc.

HOLD

Current Price

$0.91

Market Cap

126.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHPT
RANI
Founded
2007
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
125.1M
126.8M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
CHPT
RANI
Price
$6.14
$0.91
Analyst Decision
Hold
Strong Buy
Analyst Count
10
4
Target Price
$9.67
$7.50
AVG Volume (30 Days)
490.5K
1.5M
Earning Date
06-03-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
57.14
EPS
N/A
N/A
Revenue
$411,224,000.00
$1,633,000.00
Revenue This Year
$4.18
$274.77
Revenue Next Year
$16.63
$79.44
P/E Ratio
N/A
N/A
Revenue Growth
N/A
58.85
52 Week Low
$0.56
$0.39
52 Week High
$12.62
$3.87

Technical Indicators

Market Signals
Indicator
CHPT
RANI
Relative Strength Index (RSI) 63.60 45.16
Support Level $5.60 $0.45
Resistance Level $6.73 $1.54
Average True Range (ATR) 0.35 0.11
MACD 0.19 0.02
Stochastic Oscillator 83.01 60.53

Price Performance

Historical Comparison
CHPT
RANI

About CHPT ChargePoint Holdings Inc.

ChargePoint Holdings Inc designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable consumers to locate, reserve, and authenticate EV charging. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. ChargePoint derives the majority of its revenue from the United States.

About RANI Rani Therapeutics Holdings Inc.

Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.

Share on Social Networks: